THALIA THERAPEUTICS PLC (THAT) — Interim results for the six months ended 30 June 2026

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the THALIA THERAPEUTICS PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to David Solomon, CEO. Good afternoon, sir. Thank you, Lily, for the introduction, and welcome to the THALIA interim results for the first half of twenty twenty six. I'm David Solomon, CEO of THALIA THERAPEUTICS, and joining me on this call today is Luke Kerrance, our CFO. So we'll start with our safe harbor statement. THALIA THERAPEUTICS. THALIA is derived from the name in ancient Greek to mean to flourish or to bloom or to blossom. And we are really dedicated to building a new RNA therapeutics leader in Europe and also globally. We have now a diversified portfolio of innovative RNA therapeutics to primarily treat cancer, and we'll touch on our medicine for a type of leukemia, and also to treat cardiovascular disease. We'll talk about how we conduct ourselves in cardiovascular risk risk reduction. Joining me is an experienced management team and experienced board, many with proven track records in RNA therapeutics. So we are now a clinical stage company, and we're focused on RNA therapeutics broadly. And for those who may not know, RNA therapeutics is largely broken down to two main types now of therapeutics or three, but we focus on two ...